Beta-lactam and Beta-lactamase Inhibitors Market Overview
Beta-lactam and beta-lactamase inhibitors are natural, semi-synthetic, or synthetic chemical substances. Bacteria and protozoans are inhibited by them. The global Beta-lactam and Beta-lactamase Inhibitors market is expected to grow at significant rate in the forthcoming years.
The market for Beta-lactam and Beta-lactamase Inhibitors is expected to develop due to increased consumption in low and middle-income countries (LMICs) and an increase in the prevalence of infectious disorders. In addition, the market is being bolstered by the development of novel techniques for new beta-lactam and beta-lactamase inhibitors for treating bacterial infections, as well as a high number of clinical trials.
On the downside, development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitorsand the time taken for the regulatory approval are some reasons that expected to hamper the growth of the market. Besides this, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are anticipated to create significant lucrative opportunities for the market players.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | By Route Of Administration, Disease, Drug Class, and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. |
Covid-19 Impact on Beta-lactam and Beta-lactamase Inhibitors Market
In addition, the current Beta-lactam and Beta-lactamase Inhibitors Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Beta-lactam and Beta-lactamase Inhibitors Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Beta-lactam and Beta-lactamase Inhibitors Market Segment Overview
Based on the Drug Class, the Cephalosporin segment grasp the major share in the market and is estimated to continue this trend during forecast period. This is mostly due to its broad-spectrum activity and the introduction of next-generation cephalosporins that can combat antimicrobial resistance. In addition, it treats infections caused by a variety of germs. As a result, cephalosporin is in high demand among healthcare practitioners and patients, boosting the global market's growth. According to Disease, the Complicated Intra-Abdominal Infections (cIAI) is the largest segment in the market. This is attributed to the rise in burden of sepsis and rapid increase in mortality rate with greater disease severity across the world.
Beta-lactam and Beta-lactamase Inhibitors Market, By Route Of Administration
· Oral
· Intravenous
· Others
Beta-lactam and Beta-lactamase Inhibitors Market, By Disease
· Urinary Tract Infection (excluding cUTI)
· Respiratory Infection
· Skin Infection
· Complicated Urinary Tract Infection (cUTI)
· Complicated Intra-Abdominal Infections (cIAI)
· Nosocomial Pneumonia
· Blood Stream Infection
· Other
Beta-lactam and Beta-lactamase Inhibitors Market, By Drug Class
· Penicillin
· Cephalosporin
· Carbapenem
· Monobactam
· Combination
Beta-lactam and Beta-lactamase Inhibitors Regional Overview
Geographically, LAMEA is expected to show the highest growth during the forecast period. This is due to the easy accessibility of beta-lactam and beta-lactamase inhibitors over-the-counter as well as there are no regulation or restrictions on their use in this region. On the other hand, Asia-Pacific is another major region for market. This is because of the increase in consumption of beta-lactam and beta-lactamase inhibitors, easy accessibility of these drugs, and rise in sale of beta-lactam and beta-lactamase inhibitors without prescription.
Beta-lactam and Beta-lactamase Inhibitors Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Beta-lactam and Beta-lactamase Inhibitors Market, Key Players
· Abbott Laboratories
· Allergan Plc.
· F. Hoffmann-La Roche Ltd.
· GlaxoSmithKline plc
· Merck & Co. Inc.
· Mylan N.V.
· Novartis International AG (Sandoz)
· Pfizer Inc.
· Sanofi
· Teva Pharmaceutical Industries Ltd.
Frequently Asked Questions (FAQ) :
Q1. What is the total CAGR expected to be recorded for the Beta-lactam and Beta-lactamase Inhibitors market during the forecast period?
The Beta-lactam and Beta-lactamase Inhibitors market is expected to record a CAGR of ~ 2 % during the forecast period.
Q2. What are the driving factors for the Beta-lactam and Beta-lactamase Inhibitors market?
Increased consumption in low and middle-income countries (LMICs) and an increase in the prevalence of infectious disorders are some major factors that boosting the growth of the Beta-lactam and Beta-lactamase Inhibitors market.
Q3. What are the restraining factors for the Beta-lactam and Beta-lactamase Inhibitors market?
The development of antibiotic resistance, driven by misuse of beta-lactam and beta-lactamase inhibitors and the time taken for the regulatory approval are some major factors that hamper the growth of the global Beta-lactam and Beta-lactamase Inhibitors market.
Q4. Which segment is projected to hold the largest share in the Beta-lactam and Beta-lactamase Inhibitors Market. ?
The Cephalosporin segment is projected to hold the largest share in the Beta-lactam and Beta-lactamase Inhibitors Market.
Q5. Which are the prominent players in the Beta-lactam and Beta-lactamase Inhibitors Market?
Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. are some key players in the Beta-lactam and Beta-lactamase Inhibitors Market.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Route Of Administration
- 5.2.1. Oral
- 5.2.2. Intravenous
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast – By Disease
- 5.3.1. Urinary Tract Infection (excluding cUTI)
- 5.3.2. Respiratory Infection
- 5.3.3. Skin Infection
- 5.3.4. Complicated Urinary Tract Infection (cUTI)
- 5.3.5. Complicated Intra-Abdominal Infections (cIAI)
- 5.3.6. Nosocomial Pneumonia
- 5.3.7. Blood Stream Infection
- 5.3.8. Other
- 5.4. Market Analysis, Insights and Forecast – By Drug Class
- 5.4.1. Penicillin
- 5.4.2. Cephalosporin
- 5.4.3. Carbapenem
- 5.4.4. Monobactam
- 5.4.5. Combination
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East and Africa
6. North America Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Route Of Administration
- 6.2.1. Oral
- 6.2.2. Intravenous
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast – By Disease
- 6.3.1. Urinary Tract Infection (excluding cUTI)
- 6.3.2. Respiratory Infection
- 6.3.3. Skin Infection
- 6.3.4. Complicated Urinary Tract Infection (cUTI)
- 6.3.5. Complicated Intra-Abdominal Infections (cIAI)
- 6.3.6. Nosocomial Pneumonia
- 6.3.7. Blood Stream Infection
- 6.3.8. Other
- 6.4. Market Analysis, Insights and Forecast – By Drug Class
- 6.4.1. Penicillin
- 6.4.2. Cephalosporin
- 6.4.3. Carbapenem
- 6.4.4. Monobactam
- 6.4.5. Combination
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Route Of Administration
- 7.2.1. Oral
- 7.2.2. Intravenous
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast – By Disease
- 7.3.1. Urinary Tract Infection (excluding cUTI)
- 7.3.2. Respiratory Infection
- 7.3.3. Skin Infection
- 7.3.4. Complicated Urinary Tract Infection (cUTI)
- 7.3.5. Complicated Intra-Abdominal Infections (cIAI)
- 7.3.6. Nosocomial Pneumonia
- 7.3.7. Blood Stream Infection
- 7.3.8. Other
- 7.4. Market Analysis, Insights and Forecast – By Drug Class
- 7.4.1. Penicillin
- 7.4.2. Cephalosporin
- 7.4.3. Carbapenem
- 7.4.4. Monobactam
- 7.4.5. Combination
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Route Of Administration
- 8.2.1. Oral
- 8.2.2. Intravenous
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast – By Disease
- 8.3.1. Urinary Tract Infection (excluding cUTI)
- 8.3.2. Respiratory Infection
- 8.3.3. Skin Infection
- 8.3.4. Complicated Urinary Tract Infection (cUTI)
- 8.3.5. Complicated Intra-Abdominal Infections (cIAI)
- 8.3.6. Nosocomial Pneumonia
- 8.3.7. Blood Stream Infection
- 8.3.8. Other
- 8.4. Market Analysis, Insights and Forecast – By Drug Class
- 8.4.1. Penicillin
- 8.4.2. Cephalosporin
- 8.4.3. Carbapenem
- 8.4.4. Monobactam
- 8.4.5. Combination
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Route Of Administration
- 9.2.1. Oral
- 9.2.2. Intravenous
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast – By Disease
- 9.3.1. Urinary Tract Infection (excluding cUTI)
- 9.3.2. Respiratory Infection
- 9.3.3. Skin Infection
- 9.3.4. Complicated Urinary Tract Infection (cUTI)
- 9.3.5. Complicated Intra-Abdominal Infections (cIAI)
- 9.3.6. Nosocomial Pneumonia
- 9.3.7. Blood Stream Infection
- 9.3.8. Other
- 9.4. Market Analysis, Insights and Forecast – By Drug Class
- 9.4.1. Penicillin
- 9.4.2. Cephalosporin
- 9.4.3. Carbapenem
- 9.4.4. Monobactam
- 9.4.5. Combination
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Abbott Laboratories
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Allergan Plc.
- 10.6. F. Hoffmann-La Roche Ltd.
- 10.7. GlaxoSmithKline plc
- 10.8. Merck & Co. Inc.
- 10.9. Mylan N.V.
- 10.10. Novartis International AG (Sandoz)
- 10.11. Pfizer Inc.
- 10.12. Sanofi
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
